van Burik Jo-Anne H
University of Minnesota, 420 Delaware Street SE, Minneapolis, MN 55455, USA.
Curr Opin Infect Dis. 2005 Dec;18(6):479-83. doi: 10.1097/01.qco.0000185984.57135.ad.
For pancreas, liver, and hematopoietic stem cell transplant recipients, no antifungal prophylaxis led to a high rate of and high morbidity from fungal infection. With the use of fluconazole as prophylaxis since the early 1990s, there have been shifts in the types of infecting fungal pathogens, documentation of resistance among fungal organisms, and changes in transplant practices. The aim of this article is to review recent clinical trials regarding antifungal chemoprophylaxis among several populations of high risk patients.
Itraconazole, micafungin, and posaconazole have been studied as alternatives to fluconazole prophylaxis. Itraconazole showed no dramatic improvement over fluconazole as prophylaxis during liver and hematopoietic stem cell transplantation, primarily due to gastrointestinal side effects. In addition, detrimental changes to cyclophosphamide metabolism were noted for hematopoietic stem cell transplant recipients. Micafungin was superior to fluconazole during the pre-engraftment period of hematopoietic stem cell transplantation, because it was able to prevent mold infections, required less switches to empirical antifungal therapy, and functioned as well as fluconazole in preventing yeast infections. Posaconazole was compared to fluconazole during a 16-week prophylaxis period during graft-versus-host disease, but results of this study are still forthcoming. Aerosolized amphotericin products appear to be safe for lung transplant recipients.
Fluconazole remains the standard agent for prophylaxis against invasive fungal infections for pancreas, liver, and hematopoietic stem cell transplant recipients. Micafungin is superior to fluconazole with minimal toxicity for use in the pre-engraftment period of hematopoietic stem cell transplantation. The optimal agent for prophylaxis later following transplant, if mold coverage is desired during prolonged immunosuppression, has not been determined.
对于胰腺、肝脏和造血干细胞移植受者,不进行抗真菌预防会导致真菌感染率高且发病率高。自20世纪90年代初开始使用氟康唑进行预防以来,感染真菌病原体的类型、真菌生物体耐药性的记录以及移植实践都发生了变化。本文旨在综述近期关于高危患者群体抗真菌化学预防的临床试验。
已对伊曲康唑、米卡芬净和泊沙康唑作为氟康唑预防的替代药物进行了研究。在肝脏和造血干细胞移植期间,伊曲康唑作为预防药物并未显示出比氟康唑有显著改善,主要是由于胃肠道副作用。此外,造血干细胞移植受者的环磷酰胺代谢出现了有害变化。在造血干细胞移植的植入前期,米卡芬净优于氟康唑,因为它能够预防霉菌感染,减少转为经验性抗真菌治疗的次数,并且在预防酵母菌感染方面与氟康唑效果相当。在移植物抗宿主病的16周预防期内,将泊沙康唑与氟康唑进行了比较,但该研究结果尚未公布。雾化两性霉素产品似乎对肺移植受者是安全的。
氟康唑仍然是胰腺、肝脏和造血干细胞移植受者预防侵袭性真菌感染的标准药物。在造血干细胞移植的植入前期,米卡芬净优于氟康唑,且毒性最小。如果在长期免疫抑制期间需要覆盖霉菌,移植后期预防的最佳药物尚未确定。